Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Posts Q3 Revenues Increase of 6 Percent as MDx Sales Inch up 1 Percent

NEW YORK (GenomeWeb) – Abbott reported today that its third quarter sales increased nearly 6 percent year over year, while its molecular diagnostics business saw sales increase just under 1 percent.

Abbott reported total revenues of $5.10 billion, up from $4.83 billion for the third quarter of 2013, but falling short of the consensus Wall Street estimate of $5.60 billion. Sales for its Nutrition business climbed around 9 percent to $1.79 billion, while sales for the Established Pharmaceuticals business were up nearly 12 percent at $771 million, and Medical Devices revenue dropped 1 percent to $1.33 billion.

Abbott's Diagnostics business reported 5 percent sales growth to $1.18 billion. Its molecular diagnostics sales for the quarter were $118 million, slightly above the $117 million reported in Q3 last year. Abbott attributed the tepid sales growth to "market dynamics in its smaller businesses, as well as the timing of tenders in its infectious disease business in several emerging markets."

Its core laboratory diagnostics sales were up around 5 percent to $955 million, and its point-of-care diagnostics sales increased 7 percent to $107.

Abbott posted net income of $538 million, or $.36 per share, versus a profit of $966 million, or $.61 per share, in Q3 2013. Adjusted for one-time gains and costs, the firm posted EPS of $.62 versus $.55 for Q3 2013, and above the Wall Street consensus estimate of $.59.

The firm said that it has raised the mid-point and narrowed its FY 2014 EPS guidance to a range between $2.25 and $2.27, excluding specified items. It previously had guided to a range of $2.19 to $2.29.

In early Wednesday trade on the New York Stock Exchange, shares of Abbott were down a fraction of 1 percent at $42.17.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.